5 Undervalued Biotechnology & Medical Research Stocks for Monday, June 17
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Monday, June 17 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Commentary & Analysis
6 Undervalued Biotechnology & Medical Research Stocks for Thursday, May 16
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Thursday, May 16 based on AAII’s Stock Grades.Jenna Brashear
7 Undervalued Biotechnology & Medical Research Stocks for Monday, June 19
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Monday, June 19 based on AAII’s Stock Grades.Grace Malone
Is Midatech Pharma PLC-ADR (BDRX) Stock a Good Investment?
Learn more about Midatech Pharma PLC-ADR's (BDRX) stock grades for Momentum and Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | BDRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.1 | $252.6 | 1% |
|
| Shares Out (Mil) | 0.2 | 52.3 | 1% |
|
| Institutional Ownership | 64.9% | 92.1% | 41% |
|
| Float (Mil) | 0.7 | 40.2 | 1% |
|
| Beta | 1.21 | 0.95 | 71% |
|
| Avg Daily Volume (000s) | 414 | 455 | 56% |
|
| Price Change (52-week) |
(96.9%) | 52.9% | 2% |
|
| Growth | BDRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 22.3% | (9.9%) | 76% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BDRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($9) | ($43) | 30% |
|
| EPS (TTM) | ($78.309) | ($1.600) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | $9 | $5 | 57% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($11) | $180 | 2% |
|
| Valuation | BDRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.04 | 2.56 | 1% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | BDRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (40.0%) | (49.8%) | 14% |
|
| ROE | (66.7%) | (55.5%) | 13% |
|
| Liabilities to Assets | 37.3% | 30.3% | 28% |
|
| F-Score | 4 | 3 | na |
|
Biodexa Pharmaceuticals Plc did not pass any screens on 7/31/2026.
